Leukemia, acute lymphocytic, susceptibility to, 1

Summary

Leukemia, acute lymphocytic, susceptibility to, 1 (MONDO:0013108) is a cancer with 2 cohort genes (1 CIViC-evidence somatic driver; 1 ClinVar predisposition record) and 78 clinical trials. Top therapeutic interventions include daunorubicin, inotuzumab ozogamicin, and blinatumomab.

At a glance

• Classification: Cancer
• Cohort genes: 2
• ClinVar variants: 1
• Clinical trials: 78

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	leukemia, acute lymphocytic, susceptibility to, 1
Mondo ID	MONDO:0013108
OMIM	613065
UMLS	C2751595
MedGen	442767
GARD	0027842
Is cancer (heuristic)	yes

Also known as: ALL · leukemia, acute lymphoblastic · leukemia, acute lymphoblastic, somatic · leukemia, acute lymphocytic, Philadelphia chromosome positive, somatic · leukemia, acute lymphocytic, susceptibility to, 1 · leukemia, T-cell acute lymphoblastic, somatic · leukemia, T-cell acute lymphocytic, somatic · T-cell acute lymphoblastic leukemia, somatic

Data availability: 1 ClinVar variant · 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › hereditary neoplastic syndrome › leukemia, acute lymphocytic, susceptibility to, 1

Related subtypes (116): mosaic variegated aneuploidy syndrome, tuberous sclerosis, hereditary breast ovarian cancer syndrome, hereditary multiple osteochondromas, nevoid basal cell carcinoma syndrome, leukemia, chronic lymphocytic, susceptibility to, 2, blue rubber bleb nevus, cherubism, Beckwith-Wiedemann syndrome, multiple self-healing squamous epithelioma, erythroleukemia, familial, susceptibility to, goiter, multinodular 1, with or without Sertoli-Leydig cell tumors, hyperparathyroidism 2 with jaw tumors, Kaposi sarcoma, susceptibility to, hereditary leiomyomatosis and renal cell cancer, susceptibility to uveal melanoma, melanoma and neural system tumor syndrome, nasopharyngeal carcinoma, susceptibility to, 2, WAGR syndrome, neuroblastoma, susceptibility to, 1, Rothmund-Thomson syndrome, mismatch repair cancer syndrome 1, Wiskott-Aldrich syndrome, N syndrome, hereditary thrombocytopenia and hematologic cancer predisposition syndrome, prostate cancer/brain cancer susceptibility, Brooke-Spiegler syndrome, pancreatic cancer, susceptibility to, 1, Carney-Stratakis syndrome, nasopharyngeal carcinoma, susceptibility to, 1, ovarian cancer, susceptibility to, 1, colorectal cancer, susceptibility to, 1, lung cancer susceptibility 1, leukemia, chronic lymphocytic, susceptibility to, 1, Kostmann syndrome, colorectal cancer, susceptibility to, 2, colorectal cancer, susceptibility to, 3, colorectal cancer, susceptibility to, 5, colorectal cancer, susceptibility to, 6, colorectal cancer, susceptibility to, 7, leukemia, chronic lymphocytic, susceptibility to, 3, leukemia, chronic lymphocytic, susceptibility to, 4, leukemia, chronic lymphocytic, susceptibility to, 5, lung cancer susceptibility 3, colorectal cancer, susceptibility to, 8, colorectal cancer, susceptibility to, 9, colorectal cancer, susceptibility to, 10, colorectal cancer, susceptibility to, 11, lung cancer susceptibility 4, neuroblastoma, susceptibility to, 3, neuroblastoma, susceptibility to, 4, neuroblastoma, susceptibility to, 5, neuroblastoma, susceptibility to, 6, leukemia, acute lymphocytic, susceptibility to, 2, lung cancer susceptibility 5, BAP1-related tumor predisposition syndrome, familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome, Maffucci syndrome, basal cell carcinoma, susceptibility to, 7, colorectal cancer, susceptibility to, 12, leukemia, acute lymphoblastic, susceptibility to, 3, cholangiocarcinoma, susceptibility to, progeroid features-hepatocellular carcinoma predisposition syndrome, neuroblastoma, susceptibility to, 7, DDX41-related hematologic malignancy predisposition syndrome, nasopharyngeal carcinoma, susceptibility to, 3, familial isolated hyperparathyroidism, intestinal polyposis syndrome, dyskeratosis congenita, familial rhabdoid tumor, multiple endocrine neoplasia, hereditary pheochromocytoma-paraganglioma, PTEN hamartoma tumor syndrome, familial multiple fibrofolliculoma, hereditary retinoblastoma, familial atypical multiple mole melanoma syndrome, hereditary nonpolyposis colon cancer, Li-Fraumeni syndrome, Cobb syndrome, neurofibromatosis, susceptibility to familial cutaneous melanoma, pancreatic cancer, susceptibility to, 5, leukemia, acute myeloid, susceptibility to, diffuse gastric and lobular breast cancer syndrome with or without cleft lip and/or palate, glioma susceptibility, hemangioma, capillary infantile, susceptibility to, CDH1-related diffuse gastric and lobular breast cancer syndrome, NTHL1-deficiency tumor predisposition syndrome, SAMD9-related spectrum and myeloid neoplasm risk, neuroblastoma, susceptibility to, 2, BARD1-related cancer predisposition, BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, ATM-related cancer predisposition, CHEK2-related cancer predisposition, PALB2-related cancer predisposition, RAD51C-related cancer predisposition, RAD51D-related cancer predisposition, Li-fraumeni-like syndrome, breast cancer, familial, susceptibility to, 1, breast cancer, familial, susceptibility to, 2, breast cancer, familial, susceptibility to, 3, colorectal cancer, susceptibility to, 4, colorectal cancer, susceptibility to, on chromosome 15, ovarian cancer, familial, susceptibility to, 1, ovarian cancer, familial, susceptibility to, 2, ovarian cancer, familial, susceptibility to, 3, inherited hematologic cancer-predisposing syndrome, mosaic neurofibromatosis/schwannomatosis, tumor predisposition syndrome 2, prostate cancer, hereditary, X-linked 3, follicular lymphoma, susceptibility to, GPR161-related medulloblastoma predisposition, SAMD9L-related spectrum and myeloid neoplasm risk, HAVCR2-related cancer predisposition, EGLN1-related erythrocytosis and pheochromocytoma/paraganglioma predisposition

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 pathogenic/likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
461506	NM_002485.5(NBN):c.1377dup (p.Gln460fs)	NBN	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 1 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
BAX			CIViC #550

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
BAX	Limited	Unknown	leukemia, acute lymphocytic, susceptibility to, 1

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
NBN	Orphanet:1331	Familial prostate cancer
NBN	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
NBN	Orphanet:647	Nijmegen breakage syndrome

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BAX	HGNC:959	ENSG00000087088	Q07812	Apoptosis regulator BAX	gencc
NBN	HGNC:7652	ENSG00000104320	O60934	Nibrin	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BAX	Apoptosis regulator BAX	Plays a role in the mitochondrial apoptotic process.
NBN	Nibrin	Component of the MRN complex, which plays a central role in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity and meiosis.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	2	1.8×	0.312

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BAX	Other/Unknown	no		Bcl2-like, Bcl2_BH1_motif_CS, Bcl2_BH2_motif_CS
NBN	Other/Unknown	no		FHA_dom, BRCT_dom, SMAD_FHA_dom_sf

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
granulocyte	1
mucosa of transverse colon	1
stromal cell of endometrium	1
cauda epididymis	1
endometrium epithelium	1
mammary duct	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BAX	244	ubiquitous	marker	mucosa of transverse colon, stromal cell of endometrium, granulocyte
NBN	299	ubiquitous	marker	endometrium epithelium, mammary duct, cauda epididymis

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
NBN	1,989
BAX	543

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BAX	Q07812	37
NBN	O60934	7

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 62. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Activation, translocation and oligomerization of BAX	1	2855.0×	0.011	BAX
NTRK3 as a dependence receptor	1	1903.3×	0.011	BAX
Sensing of DNA Double Strand Breaks	1	951.7×	0.011	NBN
Release of apoptotic factors from the mitochondria	1	815.7×	0.011	BAX
Signaling by NTRK3 (TRKC)	1	571.0×	0.011	BAX
Defective homologous recombination repair (HRR) due to PALB2 loss of function	1	475.8×	0.011	NBN
Apoptotic factor-mediated response	1	439.2×	0.011	BAX
HDR through MMEJ (alt-NHEJ)	1	439.2×	0.011	NBN
Diseases of DNA Double-Strand Break Repair	1	407.9×	0.011	NBN
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	1	407.9×	0.011	NBN
Regulated Necrosis	1	356.9×	0.011	BAX
Resolution of D-Loop Structures	1	317.2×	0.011	NBN
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	1	300.5×	0.011	BAX
Diseases of DNA repair	1	285.5×	0.011	NBN
TP53 Regulates Transcription of Cell Death Genes	1	271.9×	0.011	BAX
TP53 Regulates Transcription of Cell Cycle Genes	1	271.9×	0.011	BAX
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	1	271.9×	0.011	BAX
DNA Double Strand Break Response	1	237.9×	0.011	NBN
Impaired BRCA2 binding to PALB2	1	228.4×	0.011	NBN
Pyroptosis	1	211.5×	0.011	BAX
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	1	211.5×	0.011	NBN
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	1	211.5×	0.011	NBN
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	1	211.5×	0.011	NBN
Transcriptional Regulation by TP53	2	62.1×	0.011	NBN, BAX
RNA Polymerase II Transcription	2	22.5×	0.011	NBN, BAX
Gene expression (Transcription)	2	17.8×	0.011	NBN, BAX
Generic Transcription Pathway	2	15.1×	0.011	NBN, BAX
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	1	196.9×	0.011	NBN
Homologous DNA Pairing and Strand Exchange	1	190.3×	0.011	NBN
Homology Directed Repair	1	154.3×	0.012	NBN

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
intrinsic apoptotic signaling pathway	2	358.6×	9e-04	NBN, BAX
T cell homeostatic proliferation	1	8426.0×	0.002	BAX
release of matrix enzymes from mitochondria	1	8426.0×	0.002	BAX
positive regulation of developmental pigmentation	1	8426.0×	0.002	BAX
B cell negative selection	1	4213.0×	0.002	BAX
B cell homeostatic proliferation	1	4213.0×	0.002	BAX
regulation of nitrogen utilization	1	4213.0×	0.002	BAX
development of animal secondary sexual characteristics	1	4213.0×	0.002	BAX
telomere maintenance via telomere trimming	1	4213.0×	0.002	NBN
B cell receptor apoptotic signaling pathway	1	4213.0×	0.002	BAX
positive regulation of motor neuron apoptotic process	1	4213.0×	0.002	BAX
regulation of cell cycle	2	74.6×	0.002	NBN, BAX
retinal cell programmed cell death	1	2808.7×	0.002	BAX
apoptotic process involved in mammary gland involution	1	2808.7×	0.002	BAX
apoptotic process involved in embryonic digit morphogenesis	1	2808.7×	0.002	BAX
regulation of mitochondrial membrane permeability involved in programmed necrotic cell death	1	2808.7×	0.002	BAX
positive regulation of B cell apoptotic process	1	2106.5×	0.002	BAX
telomeric 3’ overhang formation	1	2106.5×	0.002	NBN
post-embryonic camera-type eye morphogenesis	1	2106.5×	0.002	BAX
protein insertion into mitochondrial membrane	1	2106.5×	0.002	BAX
positive regulation of apoptotic process involved in mammary gland involution	1	2106.5×	0.002	BAX
positive regulation of mitochondrial membrane permeability involved in apoptotic process	1	2106.5×	0.002	BAX
positive regulation of reproductive process	1	2106.5×	0.002	BAX
negative regulation of telomere capping	1	1685.2×	0.003	NBN
blastocyst growth	1	1404.3×	0.003	NBN
establishment or maintenance of transmembrane electrochemical gradient	1	1404.3×	0.003	BAX
negative regulation of endoplasmic reticulum calcium ion concentration	1	1404.3×	0.003	BAX
regulation of mammary gland epithelial cell proliferation	1	1404.3×	0.003	BAX
Sertoli cell proliferation	1	1404.3×	0.003	BAX
apoptotic process involved in blood vessel morphogenesis	1	1404.3×	0.003	BAX

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
BAX	1	1
NBN	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
ABT 737	1	BAX

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
BAX	49	Binding:47, Functional:2
NBN	2	Binding:2

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

1 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
ABT 737	1	BAX

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	1	BAX
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	NBN

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
NBN	2	—

Clinical trials & evidence

Clinical trials

Clinical trials: 78.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	36
PHASE2	16
PHASE1	13
PHASE1/PHASE2	8
PHASE3	2
EARLY_PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04307576	PHASE3	RECRUITING	A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT02393859	PHASE3	COMPLETED	Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT03275636	PHASE2/PHASE3	COMPLETED	Haploidentical Donor vs mMUD in Hematological Malignancies
NCT03739502	PHASE2	RECRUITING	A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
NCT04644016	PHASE2	RECRUITING	Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
NCT05306301	PHASE2	ACTIVE_NOT_RECRUITING	Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
NCT05940961	PHASE2	RECRUITING	Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
NCT06101381	PHASE1/PHASE2	RECRUITING	CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma
NCT06364423	PHASE1/PHASE2	RECRUITING	Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
NCT07252336	PHASE2	RECRUITING	A Multicenter Study of CAR-T Cells in Primary Ph+All
NCT00533923	PHASE2	COMPLETED	Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
NCT00539695	PHASE2	COMPLETED	Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
NCT00636909	PHASE2	COMPLETED	Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
NCT00776373	PHASE1/PHASE2	TERMINATED	Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
NCT00814983	PHASE1/PHASE2	TERMINATED	Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft
NCT00815568	PHASE2	UNKNOWN	Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)
NCT00863148	PHASE2	COMPLETED	Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
NCT01012492	PHASE2	COMPLETED	Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
NCT01532635	PHASE2	TERMINATED	A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
NCT01866839	PHASE1/PHASE2	COMPLETED	Preventing Stem Cell Transplant Complications With a Blood Separator Machine
NCT02349178	PHASE2	TERMINATED	Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT
NCT02776605	PHASE2	UNKNOWN	Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia
NCT02795520	PHASE1/PHASE2	TERMINATED	Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
NCT02799147	PHASE1/PHASE2	COMPLETED	GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
NCT02935543	PHASE2	TERMINATED	CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
NCT04601584	PHASE1/PHASE2	UNKNOWN	GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
NCT04942730	PHASE2	COMPLETED	Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
NCT03571321	PHASE1	RECRUITING	Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
NCT05016947	PHASE1	ACTIVE_NOT_RECRUITING	Venetoclax Plus Inotuzumab for B-ALL
NCT05476770	PHASE1	RECRUITING	Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
NCT06047886	PHASE1	RECRUITING	UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
NCT00891592	PHASE1	COMPLETED	Umbilical Cord Blood Transplant for Hematological Malignancies
NCT00964873	PHASE1	COMPLETED	A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
NCT01204164	PHASE1	COMPLETED	Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
NCT01319864	PHASE1	COMPLETED	POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
NCT01593696	PHASE1	COMPLETED	Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
NCT02315612	PHASE1	COMPLETED	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
NCT03198234	PHASE1	TERMINATED	Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
NCT04327037	PHASE1	COMPLETED	Safety of Expanded Haploidentical Natural Killer Cells for Leukemia
NCT04473911	PHASE1	COMPLETED	Haplo Peripheral Blood Sct In GVHD Prevention

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DAUNORUBICIN	4	5
INOTUZUMAB OZOGAMICIN	4	3
BLINATUMOMAB	4	2
CYTARABINE	4	2
PONATINIB	4	2
ABATACEPT	4	1
BENDAMUSTINE	4	1
CLOFARABINE	4	1
ETOPOSIDE PHOSPHATE	4	1
IFOSFAMIDE	4	1
IMATINIB	4	1
IOHEXOL	4	1
IOPAMIDOL	4	1
PEGASPARGASE	4	1
TAGRAXOFUSP	4	1
THIOGUANINE	4	1
TISAGENLECLEUCEL	4	1
GANETESPIB	3	1
SULFORAPHANE	3	1
ZOTIRACICLIB CITRATE	1	1
CHEMBL1171086	0	2
CHEMBL4519289	0	2
CHEMBL1335195	0	1